Molecular mechanisms of metastasis

Journal of Surgical Oncology

Volumn 103, Issue 6, 2011, Pages 508-517

  Hoon, Dave S B ^a   Ferris, Robert ^b   Tanaka, Ryo ^a   Chong, Kelly K ^a   Alix Panabières, Catherine ^c,d   Pantel, Klaus ^e  

^a JOHN WAYNE CANCER INSTITUTE   (United States)

^b UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^c HÔPITAL SAINT ELOI   (France)

^d UNIV MONTPELLIER   (France)

^e UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

chemokine receptor; CTC; methylation; microRNA

Indexed keywords

CHEMOKINE RECEPTOR; CHEMOKINE RECEPTOR CCR1; CHEMOKINE RECEPTOR CCR10; CHEMOKINE RECEPTOR CCR2; CHEMOKINE RECEPTOR CCR3; CHEMOKINE RECEPTOR CCR4; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CCR6; CHEMOKINE RECEPTOR CCR7; CHEMOKINE RECEPTOR CCR8; CHEMOKINE RECEPTOR CCR9; CHEMOKINE RECEPTOR CX3CR1; CHEMOKINE RECEPTOR CXCR1; CHEMOKINE RECEPTOR CXCR2; CHEMOKINE RECEPTOR CXCR3; CHEMOKINE RECEPTOR CXCR4; CHEMOKINE RECEPTOR CXCR5; CHEMOKINE RECEPTOR CXCR6; CHEMOKINE RECEPTOR XCR1; LIGAND; MESSENGER RNA; MICRORNA; PROTEIN CCL1; PROTEIN CCL17; PROTEIN CCL19; PROTEIN CCL2; PROTEIN CCL20; PROTEIN CCL3; PROTEIN CCL5; PROTEIN XCL1; UNCLASSIFIED DRUG;

ARTICLE; CHROMODOMAIN HELICASE DNA BINDING PROTEIN 5 GENE; CPG ISLAND; GATA4 GENE; GENE CONTROL; MELANOMA; METASTASIS; METHYLATED IN TUMOR 1 GENE; METHYLATED IN TUMOR 12 GENE; METHYLATED IN TUMOR 17 GENE; METHYLATED IN TUMOR 2 GENE; METHYLATED IN TUMOR 25 GENE; METHYLATED IN TUMOR 3 GENE; METHYLATED IN TUMOR 31 GENE; METHYLATION; MOUTH CANCER; PLA2G2A GENE; PRIORITY JOURNAL; PROMOTER REGION; RAR BETA2 GENE; RASSF1A GENE; RETINOBLASTOMA PROTEININTERACTING ZINC FINGER 1 GENE; RUNX3 GENE; SOCS1 GENE; TFPI1 GENE; TP73 GENE; TUMOR CELL; TUMOR SUPPRESSOR GENE; WIF1 GENE;

DNA METHYLATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; HUMANS; IMMUNOHISTOCHEMISTRY; MELANOMA; MICRORNAS; MOUTH NEOPLASMS; NEOPLASM METASTASIS; NEOPLASTIC CELLS, CIRCULATING; RECEPTORS, CHEMOKINE; SKIN NEOPLASMS;

EID: 79953901990     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.21690     Document Type: Article

References (107)

1. de Maat MF, Umetani N, Sunami E, et al.: Assessment of methylation events during colorectal tumor progression by absolute quantitative analysis of methylated alleles. Mol Cancer Res 2007; 5: 461-471. (Pubitemid 46903955)
2. Herman JG, Baylin SB,: Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 2003; 349: 2042-2054. (Pubitemid 37448928)
3. Kusano M, Toyota M, Suzuki H, et al.: Genetic, epigenetic, and clinicopathologic features of gastric carcinomas with the CpG island methylator phenotype and an association with Epstein-Barr virus. Cancer 2006; 106: 1467-1479.
4. Tucker KL,: Methylated cytosine and the brain: A new base for neuroscience. Neuron 2001; 30: 649-652. (Pubitemid 32607329)
5. Vucic EA, Brown CJ, Lam WL,: Epigenetics of cancer progression. Pharmacogenomics 2008; 9: 215-234. (Pubitemid 351575091)
6. Umetani N, Takeuchi H, Fujimoto A, et al.: Epigenetic inactivation of ID4 in colorectal carcinomas correlates with poor differentiation and unfavorable prognosis. Clin Cancer Res 2004; 10: 7475-7483. (Pubitemid 39557508)
7. Ehrich M, Nelson MR, Stanssens P, et al.: Quantitative high-throughput analysis of DNA methylation patterns by base-specific cleavage and mass spectrometry. Proc Natl Acad Sci USA 2005; 102: 15785-15790. (Pubitemid 41552820)
8. Tanemura A, Terando AM, Sim MS, et al.: CpG island methylator phenotype predicts progression of malignant melanoma. Clin Cancer Res 2009; 15: 1801-1807.
9. de Maat MF, van de Velde CJ, van der Werff MP, et al.: Quantitative analysis of methylation of genomic loci in early-stage rectal cancer predicts distant recurrence. J Clin Oncol 2008; 26: 2327-2335.
10. Toyota M, Ahuja N, Suzuki H, et al.: Aberrant methylation in gastric cancer associated with the CpG island methylator phenotype. Cancer Res 1999; 59: 5438-5442. (Pubitemid 29526452)
11. Richter AM, Pfeifer GP, Dammann RH,: The RASSF proteins in cancer; from epigenetic silencing to functional characterization. Biochim Biophys Acta 2009; 1796: 114-128.
12. Davalos V, Esteller M,: MicroRNAs and cancer epigenetics: A macrorevolution. Curr Opin Oncol 2010; 22: 35-45.
13. Garzon R, Calin GA, Croce CM,: MicroRNAs in cancer. Annu Rev Med 2009; 60: 167-179.
14. Calin GA, Croce CM,: MicroRNA signatures in human cancers. Nat Rev Cancer 2006; 6: 857-866. (Pubitemid 44629897)
15. Zhang B, Pan X, Cobb GP, et al.: microRNAs as oncogenes and tumor suppressors. Dev Biol 2007; 302: 1-12. (Pubitemid 46096921)
16. Mueller DW, Bosserhoff AK,: Role of miRNAs in the progression of malignant melanoma. Br J Cancer 2009; 101: 551-556.
17. Bartels CL, Tsongalis GJ,: MicroRNAs: Novel biomarkers for human cancer. Clin Chem 2009; 55: 623-631.
18. Gaur A, Jewell DA, Liang Y, et al.: Characterization of microRNA expression levels and their biological correlates in human cancer cell lines. Cancer Res 2007; 67: 2456-2468. (Pubitemid 46548930)
19. Mueller DW, Rehli M, Bosserhoff AK,: miRNA expression profiling in melanocytes and melanoma cell lines reveals miRNAs associated with formation and progression of malignant melanoma. J Invest Dermatol 2009; 129: 1740-1751.
20. Ma Z, Lui WO, Fire A, et al.: Profiling and discovery of novel miRNAs from formalin-fixed, paraffin-embedded melanoma and nodal specimens. J Mol Diagn 2009; 11: 420-429.
21. Zhang L, Huang J, Yang N, et al.: microRNAs exhibit high frequency genomic alterations in human cancer. Proc Natl Acad Sci USA 2006; 103: 9136-9141. (Pubitemid 43902545)
22. Igoucheva O, Alexeev V,: MicroRNA-dependent regulation of cKit in cutaneous melanoma. Biochem Biophys Res Commun 2009; 379: 790-794.
23. Schultz J, Lorenz P, Gross G, et al.: MicroRNA let-7b targets important cell cycle molecules in malignant melanoma cells and interferes with anchorage-independent growth. Cell Res 2008; 18: 549-557. (Pubitemid 351630945)
24. Muller DW, Bosserhoff AK,: Integrin beta 3 expression is regulated by let-7a miRNA in malignant melanoma. Oncogene 2008; 27: 6698-6706.
25. Bemis LT, Chen R, Amato CM, et al.: MicroRNA-137 targets microphthalmia-associated transcription factor in melanoma cell lines. Cancer Res 2008; 68: 1362-1368. (Pubitemid 351346843)
26. Segura MF, Hanniford D, Menendez S, et al.: Aberrant miR-182 expression promotes melanoma metastasis by repressing FOXO3 and microphthalmia-associated transcription factor. Proc Natl Acad Sci USA 2009; 106: 1814-1819.
27. Caramuta S, Egyhazi S, Rodolfo M, et al.: MicroRNA expression profiles associated with mutational status and survival in malignant melanoma. J Invest Dermatol 2010; 130: 2062-2070.
28. Satzger I, Mattern A, Kuettler U, et al.: MicroRNA-15b represents an independent prognostic parameter and is correlated with tumor cell proliferation and apoptosis in malignant melanoma. Int J Cancer 2010; 126: 2553-2562.
29. Segura MF, Belitskaya-Levy I, Rose AE, et al.: Melanoma microRNA signature predicts post-recurrence survival. Clin Cancer Res 2010; 16: 1577-1586.
30. Kitago M, Martinez SR, Nakamura T, et al.: Regulation of RUNX3 tumor suppressor gene expression in cutaneous melanoma. Clin Cancer Res 2009; 15: 2988-2994.
31. Ito Y,: Oncogenic potential of the RUNX gene family: "Overview. " Oncogene 2004; 23: 4198-4208. (Pubitemid 38765135)
32. Ito Y,: RUNX genes in development and cancer: Regulation of viral gene expression and the discovery of RUNX family genes. Adv Cancer Res 2008; 99: 33-76. (Pubitemid 350148068)
33. Wei D, Gong W, Oh SC, et al.: Loss of RUNX3 expression significantly affects the clinical outcome of gastric cancer patients and its restoration causes drastic suppression of tumor growth and metastasis. Cancer Res 2005; 65: 4809-4816. (Pubitemid 40740819)
34. Javed A, Barnes GL, Pratap J, et al.: Impaired intranuclear trafficking of Runx2 (AML3/CBFA1) transcription factors in breast cancer cells inhibits osteolysis in vivo. Proc Natl Acad Sci USA 2005; 102: 1454-1459. (Pubitemid 40209191)
35. Young DW, Hassan MQ, Pratap J, et al.: Mitotic occupancy and lineage-specific transcriptional control of rRNA genes by Runx2. Nature 2007; 445: 442-446. (Pubitemid 46160913)
36. Chuang LS, Ito Y,: RUNX3 is multifunctional in carcinogenesis of multiple solid tumors. Oncogene 2010; 29: 2605-2615.
37. Li QL, Ito K, Sakakura C, et al.: Causal relationship between the loss of RUNX3 expression and gastric cancer. Cell 2002; 109: 113-124. (Pubitemid 34327521)
38. Kim WJ, Kim EJ, Jeong P, et al.: RUNX3 inactivation by point mutations and aberrant DNA methylation in bladder tumors. Cancer Res 2005; 65: 9347-9354. (Pubitemid 41508002)
39. Soong R, Shah N, Peh BK, et al.: The expression of RUNX3 in colorectal cancer is associated with disease stage and patient outcome. Br J Cancer 2009; 100: 676-679.
40. Poetsch M, Dittberner T, Woenckhaus C,: Microsatellite analysis at 1p36.3 in malignant melanoma of the skin: Fine mapping in search of a possible tumour suppressor gene region. Melanoma Res 2003; 13: 29-33. (Pubitemid 36269811)
41. Tsunematsu T, Kudo Y, Iizuka S, et al.: RUNX3 has an oncogenic role in head and neck cancer. PLoS ONE 2009; 4: e5892.
42. Griffiths-Jones S, Grocock RJ, van Dongen S, et al.: miRBase: MicroRNA sequences, targets and gene nomenclature. Nucleic Acids Res 2006; 34: D140-D144.
43. Rossi D, Zlotnik A,: The biology of chemokines and their receptors. Annu Rev Immunol 2000; 18: 217-242.
44. Zlotnik A, Yoshie O,: Chemokines: A new classification system and their role in immunity. Immunity 2000; 12: 121-127. (Pubitemid 30398626)
45. Lu H, Ouyang W, Huang C,: Inflammation, a key event in cancer development. Mol Cancer Res 2006; 4: 221-233.
46. Paget S,: The distribution of secondary growths in cancer of the breast. 1889. Cancer Metastasis Rev 1989; 8: 98-101.
47. Liotta LA,: An attractive force in metastasis. Nature 2001; 410: 24-25. (Pubitemid 32225818)
48. Muller A, Homey B, Soto H, et al.: Involvement of chemokine receptors in breast cancer metastasis. Nature 2001; 410: 50-56. (Pubitemid 32225831)
49. Wiley HE, Gonzalez EB, Maki W, et al.: Expression of CC chemokine receptor-7 and regional lymph node metastasis of B16 murine melanoma. J Natl Cancer Inst 2001; 93: 1638-1643. (Pubitemid 33094871)
50. Ohta M, Kitadai Y, Tanaka S, et al.: Monocyte chemoattractant protein-1 expression correlates with macrophage infiltration and tumor vascularity in human esophageal squamous cell carcinomas. Int J Cancer 2002; 102: 220-224. (Pubitemid 35222287)
51. Dhawan P, Richmond A,: Role of CXCL1 in tumorigenesis of melanoma. J Leukoc Biol 2002; 72: 9-18.
52. Shintani S, Ishikawa T, Nonaka T, et al.: Growth-regulated oncogene-1 expression is associated with angiogenesis and lymph node metastasis in human oral cancer. Oncology 2004; 66: 316-322. (Pubitemid 38822802)
53. Miyazaki H, Patel V, Wang H, et al.: Growth factor-sensitive molecular targets identified in primary and metastatic head and neck squamous cell carcinoma using microarray analysis. Oral Oncol 2006; 42: 240-256. (Pubitemid 43246756)
54. Watanabe H, Iwase M, Ohashi M, et al.: Role of interleukin-8 secreted from human oral squamous cell carcinoma cell lines. Oral Oncol 2002; 38: 670-679. (Pubitemid 34880105)
55. Delilbasi CB, Okura M, Iida S, et al.: Investigation of CXCR4 in squamous cell carcinoma of the tongue. Oral Oncol 2004; 40: 154-157. (Pubitemid 38030358)
56. Ishikawa T, Nakashiro K, Hara S, et al.: CXCR4 expression is associated with lymph-node metastasis of oral squamous cell carcinoma. Int J Oncol 2006; 28: 61-66.
57. Uchida D, Begum NM, Almofti A, et al.: Possible role of stromal-cell-derived factor-1/CXCR4 signaling on lymph node metastasis of oral squamous cell carcinoma. Exp Cell Res 2003; 290: 289-302. (Pubitemid 37272173)
58. Wang J, Xi L, Hunt JL, et al.: Expression pattern of chemokine receptor 6 (CCR6) and CCR7 in squamous cell carcinoma of the head and neck identifies a novel metastatic phenotype. Cancer Res 2004; 64: 1861-1866. (Pubitemid 38428712)
59. Burger JA, Kipps TJ,: CXCR4: A key receptor in the crosstalk between tumor cells and their microenvironment. Blood 2006; 107: 1761-1767. (Pubitemid 43289351)
60. Schioppa T, Uranchimeg B, Saccani A, et al.: Regulation of the chemokine receptor CXCR4 by hypoxia. J Exp Med 2003; 198: 1391-1402. (Pubitemid 37392484)
61. Staller P, Sulitkova J, Lisztwan J, et al.: Chemokine receptor CXCR4 downregulated by von Hippel-Lindau tumour suppressor pVHL. Nature 2003; 425: 307-311. (Pubitemid 37158407)
62. Wilson JL, Burchell J, Grimshaw MJ,: Endothelins induce CCR7 expression by breast tumor cells via endothelin receptor A and hypoxia-inducible factor-1. Cancer Res 2006; 66: 11802-11807. (Pubitemid 46094191)
63. Bachelder RE, Wendt MA, Mercurio AM,: Vascular endothelial growth factor promotes breast carcinoma invasion in an autocrine manner by regulating the chemokine receptor CXCR4. Cancer Res 2002; 62: 7203-7206. (Pubitemid 36025239)
64. Helbig G, Christopherson KW II, Bhat-Nakshatri P, et al.: NF-kappaB promotes breast cancer cell migration and metastasis by inducing the expression of the chemokine receptor CXCR4. J Biol Chem 2003; 278: 21631-21638. (Pubitemid 36792563)
65. Kulbe H, Hagemann T, Szlosarek PW, et al.: The inflammatory cytokine tumor necrosis factor-alpha regulates chemokine receptor expression on ovarian cancer cells. Cancer Res 2005; 65: 10355-10362. (Pubitemid 41743728)
66. Mburu YK, Wang J, Wood MA, et al.: CCR7 mediates inflammation-associated tumor progression. Immunol Res 2006; 36: 61-72. (Pubitemid 46398609)
67. Richmond A,: Nf-kappa B, chemokine gene transcription and tumour growth. Nat Rev Immunol 2002; 2: 664-674. (Pubitemid 37328724)
68. Mori T, Kim J, Yamano T, et al.: Epigenetic up-regulation of C-C chemokine receptor 7 and C-X-C chemokine receptor 4 expression in melanoma cells. Cancer Res 2005; 65: 1800-1807. (Pubitemid 40478607)
69. Balkwill F,: Cancer and the chemokine network. Nat Rev Cancer 2004; 4: 540-550. (Pubitemid 38868623)
70. Balkwill F,: The significance of cancer cell expression of the chemokine receptor CXCR4. Semin Cancer Biol 2004; 14: 171-179. (Pubitemid 38586742)
71. Almofti A, Uchida D, Begum NM, et al.: The clinicopathological significance of the expression of CXCR4 protein in oral squamous cell carcinoma. Int J Oncol 2004; 25: 65-71.
72. Uchida D, Begum NM, Tomizuka Y, et al.: Acquisition of lymph node, but not distant metastatic potentials, by the overexpression of CXCR4 in human oral squamous cell carcinoma. Lab Invest 2004; 84: 1538-1546. (Pubitemid 39600561)
73. Uchida D, Onoue T, Tomizuka Y, et al.: Involvement of an autocrine stromal cell derived factor-1/CXCR4 system on the distant metastasis of human oral squamous cell carcinoma. Mol Cancer Res 2007; 5: 685-694. (Pubitemid 47105487)
74. Samara GJ, Lawrence DM, Chiarelli CJ, et al.: CXCR4-mediated adhesion and MMP-9 secretion in head and neck squamous cell carcinoma. Cancer Lett 2004; 214: 231-241. (Pubitemid 39207985)
75. Onoue T, Uchida D, Begum NM, et al.: Epithelial-mesenchymal transition induced by the stromal cell-derived factor-1/CXCR4 system in oral squamous cell carcinoma cells. Int J Oncol 2006; 29: 1133-1138.
76. Humrich JY, Humrich JH, Averbeck M, et al.: Mature monocyte-derived dendritic cells respond more strongly to CCL19 than to CXCL12: Consequences for directional migration. Immunology 2006; 117: 238-247.
77. Ding Y, Shimada Y, Maeda M, et al.: Association of CC chemokine receptor 7 with lymph node metastasis of esophageal squamous cell carcinoma. Clin Cancer Res 2003; 9: 3406-3412. (Pubitemid 37082736)
78. Mashino K, Sadanaga N, Yamaguchi H, et al.: Expression of chemokine receptor CCR7 is associated with lymph node metastasis of gastric carcinoma. Cancer Res 2002; 62: 2937-2941. (Pubitemid 34525782)
79. Wang J, Zhang X, Thomas SM, et al.: Chemokine receptor 7 activates phosphoinositide-3 kinase-mediated invasive and prosurvival pathways in head and neck cancer cells independent of EGFR. Oncogene 2005; 24: 5897-5904. (Pubitemid 43080081)
80. Wang J, Seethala RR, Zhang Q, et al.: Autocrine and paracrine chemokine receptor 7 activation in head and neck cancer: Implications for therapy. J Natl Cancer Inst 2008; 100: 502-512.
81. Takeuchi H, Fujimoto A, Tanaka M, et al.: CCL21 chemokine regulates chemokine receptor CCR7 bearing malignant melanoma cells. Clin Cancer Res 2004; 10: 2351-2358. (Pubitemid 38445693)
82. Wang J, Xi L, Gooding W, et al.: Chemokine receptors 6 and 7 identify a metastatic expression pattern in squamous cell carcinoma of the head and neck. Adv Otorhinolaryngol 2005; 62: 121-133.
83. Muller A, Sonkoly E, Eulert C, et al.: Chemokine receptors in head and neck cancer: Association with metastatic spread and regulation during chemotherapy. Int J Cancer 2006; 118: 2147-2157.
84. Fordice J, Kershaw C, El-Naggar A, et al.: Adenoid cystic carcinoma of the head and neck: Predictors of morbidity and mortality. Arch Otolaryngol Head Neck Surg 1999; 125: 149-152. (Pubitemid 29085262)
85. Pantel K, Brakenhoff RH, Brandt B,: Detection, clinical relevance and specific biological properties of disseminating tumour cells. Nat Rev Cancer 2008; 8: 329-340. (Pubitemid 351596394)
86. Pantel K, Alix-Panabieres C, Riethdorf S,: Cancer micrometastases. Nat Rev Clin Oncol 2009; 6: 339-351.
87. Nagrath S, Sequist LV, Maheswaran S, et al.: Isolation of rare circulating tumour cells in cancer patients by microchip technology. Nature 2007; 450: 1235-1239.
88. Alix-Panabieres C, Riethdorf S, Pantel K,: Circulating tumor cells and bone marrow micrometastasis. Clin Cancer Res 2008; 14: 5013-5021.
89. Lu J, Fan T, Zhao Q, et al.: Isolation of circulating epithelial and tumor progenitor cells with an invasive phenotype from breast cancer patients. Int J Cancer 2010; 126: 669-683.
90. Talasaz AH, Powell AA, Huber DE, et al.: Isolating highly enriched populations of circulating epithelial cells and other rare cells from blood using a magnetic sweeper device. Proc Natl Acad Sci USA 2009; 106: 3970-3975.
91. Pinzani P, Salvadori B, Simi L, et al.: Isolation by size of epithelial tumor cells in peripheral blood of patients with breast cancer: Correlation with real-time reverse transcriptase-polymerase chain reaction results and feasibility of molecular analysis by laser microdissection. Hum Pathol 2006; 37: 711-718. (Pubitemid 43956539)
92. Wong NS, Kahn HJ, Zhang L, et al.: Prognostic significance of circulating tumour cells enumerated after filtration enrichment in early and metastatic breast cancer patients. Breast Cancer Res Treat 2006; 99: 63-69. (Pubitemid 44168604)
93. Zheng S, Lin H, Liu JQ, et al.: Membrane microfilter device for selective capture, electrolysis and genomic analysis of human circulating tumor cells. J Chromatogr A 2007; 1162: 154-161. (Pubitemid 47187403)
94. Mani SA, Guo W, Liao MJ, et al.: The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008; 133: 704-715. (Pubitemid 351636299)
95. Schwarzenbach H, Alix-Panabieres C, Muller I, et al.: Cell-free tumor DNA in blood plasma as a marker for circulating tumor cells in prostate cancer. Clin Cancer Res 2009; 15: 1032-1038.
96. Schwarzenbach H, Chun FK, Lange I, et al.: Detection of tumor-specific DNA in blood and bone marrow plasma from patients with prostate cancer. Int J Cancer 2007; 120: 1465-1471. (Pubitemid 46355381)
97. Fan T, Zhao Q, Chen JJ, et al.: Clinical significance of circulating tumor cells detected by an invasion assay in peripheral blood of patients with ovarian cancer. Gynecol Oncol 2009; 112: 185-191.
98. Bidard FC, Vincent-Salomon A, Gomme S, et al.: Disseminated tumor cells of breast cancer patients: A strong prognostic factor for distant and local relapse. Clin Cancer Res 2008; 14: 3306-3311.
99. Kim MY, Oskarsson T, Acharyya S, et al.: Tumor self-seeding by circulating cancer cells. Cell 2009; 139: 1315-1326.
100. Cristofanilli M, Budd GT, Ellis MJ, et al.: Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 2004; 351: 781-791. (Pubitemid 39095313)
101. Budd GT, Cristofanilli M, Ellis MJ, et al.: Circulating tumor cells versus imaging-predicting overall survival in metastatic breast cancer. Clin Cancer Res 2006; 12: 6403-6409. (Pubitemid 44799711)
102. Cohen SJ, Punt CJ, Iannotti N, et al.: Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. J Clin Oncol 2008; 26: 3213-3221.
103. Scher HI, Jia X, de Bono JS, et al.: Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: A reanalysis of IMMC38 trial data. Lancet Oncol 2009; 10: 233-239.
104. Scher HI, Pantel K,: Bone marrow aspiration for disseminated tumor cell detection: A must-have test or is the jury still out? J Clin Oncol 2009; 27: 1531-1533.
105. Riethdorf S, Muller V, Zhang L, et al.: Detection and HER2 expression of circulating tumor cells: Prospective monitoring in breast cancer patients treated in the neoadjuvant GeparQuattro trial. Clin Cancer Res 2010; 16: 2634-2645.
106. Maheswaran S, Sequist LV, Nagrath S, et al.: Detection of mutations in EGFR in circulating lung-cancer cells. N Engl J Med 2008; 359: 366-377.
107. Pantel K, Alix-Panabieres C,: Detection and characterization of circulating tumor cells: Challenges and perspectives In: American Association for Cancer Research 101st Annual Meeting Education Book. AACR 2010: 179-185.